X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (177) 177
Publication (21) 21
Book Chapter (5) 5
Newspaper Article (3) 3
Patent (3) 3
Book Review (2) 2
Book / eBook (1) 1
Conference Proceeding (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (40) 40
oncology (35) 35
index medicus (31) 31
female (26) 26
male (26) 26
lung cancer (25) 25
middle aged (25) 25
chemotherapy (22) 22
adult (21) 21
aged (21) 21
lung neoplasms - genetics (19) 19
carcinoma, non-small-cell lung - genetics (16) 16
lung neoplasms - drug therapy (16) 16
mutation (16) 16
gefitinib (15) 15
open-label (14) 14
cancer (13) 13
carcinoma, non-small-cell lung - drug therapy (13) 13
resistance (12) 12
review (12) 12
treatment outcome (12) 12
aged, 80 and over (11) 11
non-small cell lung cancer (11) 11
receptor, epidermal growth factor - genetics (11) 11
survival (11) 11
animals (10) 10
erlotinib (10) 10
carcinoma, non-small-cell lung - pathology (9) 9
care and treatment (9) 9
disease-free survival (9) 9
medicine, research & experimental (9) 9
melanoma (9) 9
protein kinase inhibitors - therapeutic use (9) 9
respiratory system (9) 9
lung neoplasms - pathology (8) 8
prognosis (8) 8
review article (8) 8
1st-line treatment (7) 7
activation (7) 7
adenocarcinoma (7) 7
crizotinib (7) 7
immunotherapy (7) 7
inhibitors (7) 7
lung cancer, non-small cell (7) 7
mutations (7) 7
neoplasms. tumors. oncology. including cancer and carcinogens (7) 7
non-small-cell lung cancer (7) 7
quinazolines - therapeutic use (7) 7
respiratory tract diseases (7) 7
cell lung-cancer (6) 6
child (6) 6
child, preschool (6) 6
egfr (6) 6
erlotinib hydrochloride (6) 6
medicine (6) 6
medicine, general & internal (6) 6
multidisciplinary sciences (6) 6
mutation - genetics (6) 6
neoplasm staging (6) 6
neoplasms (6) 6
nsclc (6) 6
rna, messenger - genetics (6) 6
trial (6) 6
tumors (6) 6
tyrosine kinase inhibitors (6) 6
acquired-resistance (5) 5
activating mutations (5) 5
adolescent (5) 5
analysis (5) 5
apoptosis (5) 5
article (5) 5
brca1 protein - genetics (5) 5
cell line, tumor (5) 5
egfr mutations (5) 5
growth (5) 5
health aspects (5) 5
multicenter (5) 5
protein-tyrosine kinase (5) 5
therapy (5) 5
tyrosine (5) 5
adenocarcinoma - genetics (4) 4
antineoplastic agents - therapeutic use (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
biomarkers (4) 4
braf (4) 4
drug resistance, neoplasm (4) 4
ecology (4) 4
epidermal growth factor receptors (4) 4
expression (4) 4
genetic aspects (4) 4
growth-factor-receptor (4) 4
identification (4) 4
immunohistochemistry (4) 4
infant (4) 4
kaplan-meier estimate (4) 4
metastatic melanoma (4) 4
multivariate analysis (4) 4
non-small cell lung carcinoma (4) 4
pharmacology & pharmacy (4) 4
prospective studies (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Translational Medicine, ISSN 1479-5876, 12/2010, Volume 8, Issue 1, pp. 135 - 135
Journal Article
EBioMedicine, ISSN 2352-3964, 03/2018, Volume 29, pp. 112 - 127
Epidermal growth factor receptor (EGFR)-mutation-positive non-smallcell lung cancer (NSCLC) is incurable, despite high rates of response to EGFR tyrosine... 
Resistance | CDCP1 | AXL | Lung cancer | EGFR | Combination therapies | MEDICINE, RESEARCH & EXPERIMENTAL | 1ST-LINE TREATMENT | GEFITINIB | ACTIVATION | OPEN-LABEL | SRC-FAMILY KINASES | TYROSINE KINASE INHIBITORS | GROWTH | PHASE-3 TRIAL | ERLOTINIB | RNA, Small Interfering - genetics | Cell Adhesion Molecules - agonists | Cell Adhesion Molecules - genetics | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Gene Expression Regulation, Neoplastic | Drug Resistance, Neoplasm | Lung Neoplasms - pathology | Male | Gene Expression Profiling | Antigens, CD - genetics | Proto-Oncogene Proteins - agonists | Aged, 80 and over | Adult | Female | Proteomics - methods | Neoplasm Proteins - genetics | Receptor Protein-Tyrosine Kinases - agonists | Disease Models, Animal | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | ErbB Receptors - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - genetics | Cell Survival | Proto-Oncogene Proteins - genetics | Carcinoma, Non-Small-Cell Lung - mortality | Xenograft Model Antitumor Assays | Animals | Neoplasm Proteins - agonists | Receptor Protein-Tyrosine Kinases - genetics | Models, Biological | Survival Analysis | Aged | Mice | Carcinoma, Non-Small-Cell Lung - drug therapy | Enzyme Activation | Mutation | RNA, Small Interfering - metabolism
Journal Article
Therapeutic Advances in Medical Oncology, ISSN 1758-8340, 1/2018, Volume 10, p. 1758834017745012
Treatment for advanced non-small cell lung cancer (NSCLC) has been significantly improved in recent years with the incorporation of drugs targeting... 
Targeted therapy | Advanced NSCLC | Immunotherapy | targeted therapy | 1ST-LINE TREATMENT | MULTICENTER | PHASE-III | OPEN-LABEL | RANDOMIZED CONTROLLED-TRIAL | advanced NSCLC | DURVALUMAB | CHEMOTHERAPY | EGFR MUTANT NSCLC | ONCOLOGY | immunotherapy | MUTATIONAL LANDSCAPE | DOUBLE-BLIND | Lung cancer
Journal Article
British Journal of Cancer, ISSN 0007-0920, 03/2017, Volume 116, Issue 6, pp. 802 - 810
When tumour tissue is unavailable, cell-free DNA (cfDNA)can serve as a surrogate for genetic analyses. Because mutated alleles in cfDNA are usually below 1%,... 
lung cancer | solid tumours | NGS | cfDNA | Melanoma - blood | Lung Neoplasms - drug therapy | Gastrointestinal Neoplasms - genetics | Prognosis | Prospective Studies | Follow-Up Studies | Gastrointestinal Neoplasms - drug therapy | Colorectal Neoplasms - genetics | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Gastrointestinal Neoplasms - pathology | DNA, Neoplasm - blood | Gastrointestinal Neoplasms - blood | DNA Mutational Analysis | Melanoma - genetics | Colorectal Neoplasms - drug therapy | Gastrointestinal Stromal Tumors - pathology | Aged, 80 and over | Adult | Female | High-Throughput Nucleotide Sequencing - methods | Gastrointestinal Stromal Tumors - genetics | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Colorectal Neoplasms - blood | Melanoma - pathology | Mutation - genetics | Biomarkers, Tumor - blood | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Gastrointestinal Stromal Tumors - drug therapy | Gastrointestinal Stromal Tumors - blood | Melanoma - drug therapy | Carcinoma, Non-Small-Cell Lung - blood | ROC Curve | Aged | Biomarkers, Tumor - genetics | Lung Neoplasms - blood | Carcinoma, Non-Small-Cell Lung - drug therapy | DNA, Neoplasm - genetics | Colorectal Neoplasms - pathology | Neoplasm Staging | Genetics & Genomics
Journal Article
Journal of Biogeography, ISSN 0305-0270, 08/2019, Volume 46, Issue 8, pp. 1664 - 1675
Journal Article
Therapeutic Advances in Medical Oncology, ISSN 1758-8340, 1/2018, Volume 10, p. 1758834017749748
Background: Programmed death-ligand 1 (PD-L1) may be induced by oncogenic signals or can be upregulated via interferon gamma (IFN-γ). We have explored whether... 
PD-L1 | Interferon-gamma | PD-1 | Immunotherapy | Lung cancer | Melanoma | CTLA-4 BLOCKADE | PD-1 BLOCKADE | IFN-GAMMA | VIRAL MIMICRY | melanoma | OPEN-LABEL | CHEMOTHERAPY | lung cancer | ONCOLOGY | DOUBLE-BLIND | interferon-gamma | CLINICAL-RESPONSE | EXPRESSION | T-CELLS
Journal Article
Oncotarget, ISSN 1949-2553, 04/2018, Volume 9, Issue 29, pp. 20617 - 20630
Brain metastases constitute a challenge in the management of patients with HER2-positive breast cancer treated with anti-HER2 systemic therapies. Here we... 
Metastatic breast cancer | Personalized medicine | Actionable genetic alterations | Brain metastasis | HER2-positive
Journal Article
Nature Communications, ISSN 2041-1723, 12/2017, Volume 8, Issue 1, pp. 410 - 14
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2016, Volume 34, Issue 7, pp. 661 - 668
Journal Article
EBioMedicine, ISSN 2352-3964, 03/2018, Volume 29, pp. 112 - 127
Epidermal growth factor receptor ( )-mutation-positive non-small cell lung cancer (NSCLC) is incurable, despite high rates of response to EGFR tyrosine kinase... 
Resistance | CDCP1 | AXL | Lung cancer | EGFR | Combination therapies
Journal Article